From Wikipedia, the free encyclopedia
Durimulumab is a human monoclonal antibody and which it acts on the musculoskeletal system.
|
Human monoclonal antibodies ("-u-") |
|
| "-limu-" (immune system) |
|
|
| "-kinu-" (interleukin as target) |
|
|
| "-tumu-" (cancer immunotherapy) |
Adecatumumab, Anetumumab, Belimumab, Duntumumab, Iratumumab, Lexatumumab, Lucatumumab, Mapatumumab, Ofatumumab, Panitumumab, Pritumumab, Votumumab, Zalutumumab, Zanolimumab
|
|
| "-osu-" (bone) |
|
|
| "-mulu-" (musculoskeletal) |
|
|
| "-fungu-" (fungal) |
|
|
| "-viru-" (viral) |
|
|
| "-bacu-" (bacterial) |
|
|
